Seattle Genetics Inc. | Key People and Executives
Clay B. Siegall
Chairman, President & Chief Executive Officer
Alpna Seth
Independent Director
Marc E. Lippman
Independent Director
John A. Orwin
Independent Director
Srini Akkaraju
Independent Director
David W. Gryska
Independent Director
Felix James Baker
Lead Independent Director
Daniel G. Welch
Independent Director
Nancy A. Simonian
Independent Director
Clay B. Siegall
Chairman, President & Chief Executive Officer
Todd E. Simpson
CFO & Principal Accounting Officer
Roger D. Dansey
Chief Medical Officer
Vaughn B. Himes
Chief Technical Officer
Robert J. Lechleider
Senior Vice President-Clinical Development
Darren S. Cline
Executive Vice President-Commercial
Dennis Benjamin
Senior Vice President-Translational Research
Peter D. Senter
Vice President-Chemistry
Brandi Robinson
Media Contact
Tricia Larson
Media Contact
Peggy Pinkston
Vice President-Investor Relations
Christopher Pawlowicz
Executive Vice President-Human Resources
Jean I. Liu
Executive VP-Legal Affairs & General Counsel
Elaine Waller
Executive Vice President-Regulatory Affairs
Alpna Seth
Independent Director
Marc E. Lippman
Independent Director
John A. Orwin
Independent Director
Srinivas Akkaraju
Independent Director
David W. Gryska
Independent Director
Felix James Baker
Lead Independent Director
Daniel G. Welch
Independent Director
Nancy A. Simonian
Independent Director
| Address |
21823 30th Drive SE
Bothell Washington 98021
United States
|
|
Employees
|
- |
| Website |
http://www.seattlegenetics.com |
| Updated |
07/08/2019 |
| Seattle Genetics, Inc. engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product ADCETRIS is an antibody-drug encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell lymphoma, or sALCL, and for certain types of cutaneous T-cell lymphoma, or CTCL. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. |
